Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **spinal dorsal column** is a major pathway within the central nervous system. It consists of two main fasciculi—the fasciculus gracilis and fasciculus cuneatus—which run longitudinally within the posterior (dorsal) aspect of the spinal cord. These tracts carry somatosensory information (touch, vibration, proprioceptive signals) from peripheral receptors in the skin, joints, and muscles to the medulla where they synapse with second-order neurons. The term encompasses an anatomical structure rather than a specific molecular entity. It is essential for the conscious perception of body position and tactile sensations, but is not considered a druggable therapeutic target itself[1][3]. "Spinal dorsal column" is anatomically precise but not a valid designation for a molecular or therapeutic target. The correct use is anatomical, describing a white matter tract responsible for specific sensory transmission; it is not itself a receptor, enzyme, or transport protein. Its injury or disease commonly leads to loss of fine touch and proprioception, but there are no specific drugs that interact with this "target"[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spinal dorsal column.